keyword
MENU ▼
Read by QxMD icon Read
search

Vva

keyword
https://www.readbyqxmd.com/read/28782717/in-silico-approaches-for-unveiling-novel-glycobiomarkers-in-cancer
#1
Rita Azevedo, André M N Silva, Celso A Reis, Lúcio Lara Santos, José Alexandre Ferreira
Glycosylation is one of the most common and dynamic post-translational modification of cell surface and secreted proteins. Cancer cells display unique glycosylation patterns that decisively contribute to drive oncogenic behavior, including disease progression and dissemination. Moreover, alterations in glycosylation are often responsible for the creation of protein signatures holding significant biomarker value and potential for targeted therapeutics. Accordingly, many analytical protocols have been outlined for the identification of abnormally glycosylated proteins by mass spectrometry...
August 4, 2017: Journal of Proteomics
https://www.readbyqxmd.com/read/28781968/impact-of-ospemifene-on-quality-of-life-and-sexual-function-in-young-survivors-of-cervical-cancer-a-prospective-study
#2
Nicoletta De Rosa, Giada Lavitola, Pierluigi Giampaolino, Ilaria Morra, Carmine Nappi, Giuseppe Bifulco
BACKGROUND: Cervical cancer (CC) treatments impact quality of life (QoL) and sexual function (SF) of survivors. Treatment options to reduce sexual dysfunction are limited. The aim of this study was to assess the effectiveness of ospemifene in CC survivors with clinical signs and symptoms of vulvovaginal atrophy (VVA) focusing on their QoL and SF. MATERIALS AND METHODS: Fifty-two patients with previous diagnosis of stage I-IIa CC suffering from VVA and treated with ospemifene were enrolled into a single arm prospective study...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28763401/randomized-double-blind-placebo-controlled-clinical-trial-for-evaluating-the-efficacy-of-fractional-co2-laser-compared-with-topical-estriol-in-the-treatment-of-vaginal-atrophy-in-postmenopausal-women
#3
Vera L Cruz, Marcelo L Steiner, Luciano M Pompei, Rodolfo Strufaldi, Fernando L Afonso Fonseca, Lucila H Simardi Santiago, Tali Wajsfeld, Cesar E Fernandes
OBJECTIVE: The aim of the study was to evaluate efficacy of fractional CO2 vaginal laser treatment (Laser, L) and compare it to local estrogen therapy (Estriol, E) and the combination of both treatments (Laser + Estriol, LE) in the treatment of vulvovaginal atrophy (VVA). METHODS: A total of 45 postmenopausal women meeting inclusion criteria were randomized in L, E, or LE groups. Assessments at baseline, 8 and 20 weeks, were conducted using Vaginal Health Index (VHI), Visual Analog Scale for VVA symptoms (dyspareunia, dryness, and burning), Female Sexual Function Index, and maturation value (MV) of Meisels...
July 31, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28697291/genitourinary-syndrome-of-menopause
#4
Elizabeth Farrell Am
BACKGROUND: Genitourinary syndrome of menopause (GSM) is the new term for vulvovaginal atrophy (VVA). Oestrogen deficiency symptoms in the genitourinary tract are bothersome in more than 50% of women, having an adverse impact on quality of life, social activity and sexual relationships. GSM is a chronic and progressive syndrome that is underdiagnosed and undertreated. OBJECTIVE: The aim of this article is to increase knowledge and understanding of GSM, improving the ability of healthcare professionals to discuss and obtain an appropriate history sensitively, and treat accordingly...
2017: Australian Family Physician
https://www.readbyqxmd.com/read/28655486/vaginal-atrophy-in-breast-cancer-survivors-attitude-and-approaches-among-oncologists
#5
Nicoletta Biglia, Valentina Elisabetta Bounous, Marta D'Alonzo, Laura Ottino, Valentina Tuninetti, Elisabetta Robba, Tania Perrone
BACKGROUND: Vulvovaginal atrophy (VVA) is a relevant problem for breast cancer survivors (BCSs), in particular for those who receive aromatase inhibitors (AIs). We conducted a survey, to assess the attitude of oncologists toward the diagnosis and treatment of VVA in BCSs. MATERIALS AND METHODS: In 2015, 120 computer-assisted Web interviews were performed among breast oncologists. RESULTS: According to oncologists' perceptions, 60% of postmenopausal BCSs and 39...
May 19, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28640161/combined-data-of-intravaginal-prasterone-against-vulvovaginal-atrophy-of-menopause
#6
Fernand Labrie, David F Archer, Céline Martel, Mario Vaillancourt, Marlene Montesino
OBJECTIVE: To analyze the effects of intravaginal prasterone obtained in the three randomized clinical studies performed in postmenopausal women suffering from moderate to severe (MS) dyspareunia due to vulvovaginal atrophy (VVA). METHODS: In three independent 12-week prospective, randomized, double-blind, and placebo-controlled clinical studies, the effect of daily intravaginal 0.50% (6.5 mg) prasterone was examined on four co-primary objectives in women having MS pain during sexual activity (dyspareunia), identified as their most bothersome symptom (MBS) of VVA at baseline...
June 19, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28640158/vasomotor-symptoms-are-associated-with-depressive-symptoms-in-community-dwelling-older-women
#7
Berihun M Zeleke, Robin J Bell, Baki Billah, Susan R Davis
OBJECTIVE: To assess the prevalence of, and factors associated with, moderate-to-severe depressive symptoms in community-dwelling older Australian women. METHODS: A questionnaire-based, cross-sectional study was conducted amongst community-dwelling older women. Participants were recruited between April and August 2014 from a national database based on the electoral roll. Depressive symptoms were assessed by the Beck Depression Inventory-II (BDI-II) tool. Vasomotor symptoms (VMS), vulvovaginal atrophy (VVA), and pelvic floor symptoms were assessed using validated questionnaires...
June 19, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28608667/dynamic-quadripolar-radiofrequency-treatment-of-vaginal-laxity-menopausal-vulvo-vaginal-atrophy-12-month-efficacy-and-safety
#8
Franco Vicariotto, Francesco DE Seta, Valentina Faoro, Mauro Raichi
BACKGROUND: Twelve-month extension of a previous spontaneous exploratory study investigating safety and efficacy of a new low-energy dynamic quadripolar radiofrequency (DQRF) device in: A) premenopausal women with symptoms of vaginal laxity, with special reference to dysuria, urinary incontinence and unsatisfactory sexual life (vaginal laxity arm of the study); B) postmenopausal women with vulvovaginal atrophy/genitourinary syndrome of menopause (VVA/GSM) and VVA/GSM-related symptoms (VVA/GSM arm of the study)...
August 2017: Minerva Ginecologica
https://www.readbyqxmd.com/read/28562130/effects-of-ospemifene-on-vaginal-epithelium-of-post-menopausal-women
#9
Stefania Alvisi, Maurizio Baldassarre, Valentina Martelli, Giulia Gava, Renato Seracchioli, Maria Cristina Meriggiola
Ospemifene is a selective estrogen receptor modulator used for the treatment of vulvo-vaginal atrophy (VVA) in post-menopausal women. No direct evidence of its effects on histological features of the human vagina has been reported. To evaluate the effects of ospemifene on histological parameters, glycogen content, proliferation, and estrogen receptor α expression (ERα) of vaginal epithelium in post-menopausal women. Thirty-two post-menopausal women undergoing surgical procedures were enrolled. Sixteen subjects taking ospemifene at the time of inclusion (OSP) were compared to 16 subjects not taking any hormone (CTL)...
May 31, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28539177/relationship-between-changes-in-vulvar-vaginal-atrophy-and-changes-in-sexual-functioning
#10
JoAnn V Pinkerton, Andrew G Bushmakin, Barry S Komm, Lucy Abraham
OBJECTIVE: Conjugated estrogens/bazedoxifene (CE/BZA) has demonstrated benefit in vulvar-vaginal atrophy (VVA, part of genitourinary syndrome of menopause) and the sexual function domain of the Menopause-specific Quality of Life (MENQOL) questionnaire. The study's objective was to determine the relationship of VVA symptoms and clinical parameters with MENQOL sexual functioning in postmenopausal women receiving VVA treatment. STUDY DESIGN: Post hoc analysis data were derived from the 12-week SMART-3 trial, which evaluated CE/BZA's effect on VVA in nonhysterectomized postmenopausal women (aged 40-65 years) experiencing one or more moderate to severe VVA symptoms (dryness, itching/irritation, pain with intercourse) and vaginal pH>5...
June 2017: Maturitas
https://www.readbyqxmd.com/read/28503946/fractional-co2-laser-therapy-a-new-challenge-for-vulvovaginal-atrophy-in-postmenopausal-women
#11
G P Siliquini, V Tuninetti, V E Bounous, F Bert, N Biglia
OBJECTIVE: To evaluate the effects of CO2 laser in the treatment of vulvovaginal atrophy (VVA) in postmenopausal women. METHODS: VVA was assessed in 87 postmenopausal women (mean age 58.6 ± 6.9 years) before and after the treatment. The protocol consisted of three monthly treatments and included the treatment of vulva. Subjective measures included VAS (Visual Analog Scale) both for vaginal dryness and dyspareunia; DIVA (Day-by-day Impact of Vaginal Aging); a questionnaire on treatment satisfaction and one about the degree of pain during the procedure...
May 15, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28490209/retrospective-analysis-in-46-women-with-vulvovaginal-atrophy-treated-with-ospemifene-for-12-weeks-improvement-in-overactive-bladder-symptoms
#12
Michele Carlo Schiavi, Marzio Angelo Zullo, Pierangelo Faiano, Ottavia D'Oria, Giovanni Prata, Vanessa Colagiovanni, Andrea Giannini, Chiara Di Tucci, Giorgia Perniola, Violante Di Donato, Marco Monti, Ludovico Muzii, Pierluigi Benedetti Panici
AIMS: The aim of this study was to assess the effectiveness and safety of ospemifene in the improvement of overactive bladder (OAB) symptoms in postmenopausal women affected by vulvovaginal atrophy (VVA). METHODS: Forty-six postmenopausal patients affected by VVA with OAB syndrome were enrolled for the study. All patients received Ospemifene 60 mg for 12 weeks. Clinical examination, 3-day voiding diary, urodynamic testing, ultrasound measurement of endometrial and bladder wall thickness (BWT) and the Vaginal Health Index (VHI) were performed at baseline and 12 weeks...
May 11, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28479073/-macroscopic-description-of-placental-vascular-anastomoses-after-dye-injection-for-the-comprehension-of-monochorionic-pregnancy-complications
#13
A Atallah, P-A Bolze, A Buenerd, S Marino, J Massardier, P Gaucherand, M Massoud
OBJECTIVES: The aim of the study is to compare placental monochorionic angioarchitecture complicated with twin-oligohydramnios-polyhydramnios sequence (TOPS), twin anemia polycythemia sequence (TAPS), twin reversed arterial perfusion (TRAP) and selective intra uterine growth restriction (sIUGR) to normal uneventful monochorionic placenta. METHODS: Between December 2012 and December 2015, monochorionic placenta has been studied at the multiple pregnancy care center of the Femme-Mère-Enfant Hospital in Lyon...
May 2017: Gynecologie, Obstetrique, Fertilite & Senologie
https://www.readbyqxmd.com/read/28419068/visual-improvements-in-vaginal-mucosa-correlate-with-symptoms-of-vva-data-from-a-double-blind-placebo-controlled-trial
#14
James A Simon, David F Archer, Risa Kagan, Brian Bernick, Shelli Graham, Ginger D Constantine, Sebastian Mirkin
OBJECTIVE: To evaluate the response of the vaginal mucosa with TX-004HR and its correlation with vulvar and vaginal atrophy (VVA) symptoms, and whether visual examination is a useful measure for assessing VVA. METHODS: REJOICE was a 12-week, phase 3, multicenter, randomized, double-blind, placebo-controlled study of a vaginal, muco-adhesive, 17β-estradiol softgel capsule (TX-004HR 4, 10, and 25 μg) in postmenopausal women with VVA and moderate-to-severe dyspareunia...
April 17, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28398023/clinical-profile-of-women-with-vva-who-are-not-candidates-for-local-vaginal-oestrogen-therapy
#15
Rossella E Nappi, Filippo Murina, Giuseppina Perrone, Paola Villa, Nicoletta Biglia
Vulvar and vaginal atrophy (VVA) is a chronic medical condition in postmenopausal women, which is predominantly due to a permanent cessation of ovarian oestrogen production. Current available treatment options for VVA are over-the-counter (OTC) symptomatic relief products or local oestrogen therapy (LET) aiming to treat this underlying atrophic condition. Recent surveys indicated that these products decrease sexual spontaneity, are messy and indiscrete. Ospemifene is an oral daily drug, which has proven to treat vaginal dryness and dyspareunia effectively...
April 10, 2017: Minerva Ginecologica
https://www.readbyqxmd.com/read/28388560/galnt6-expression-enhances-aggressive-phenotypes-of-ovarian-cancer-cells-by-regulating-egfr-activity
#16
Tzu-Chi Lin, Syue-Ting Chen, Min-Chuan Huang, John Huang, Chia-Lang Hsu, Hsueh-Fen Juan, Ho-Hsiung Lin, Chi-Hau Chen
Ovarian cancer is the most lethal of the gynecologic malignancies. N-acetylgalactosaminyltransferase 6 (GALNT6), an enzyme that mediates the initial step of mucin type-O glycosylation, has been reported to regulate mammary carcinogenesis. However, the expression and role of GALNT6 in ovarian cancer are still unclear. Here we showed that high GALNT6 expression correlates with increased recurrence, lymph node metastasis, and chemoresistance in ovarian endometrioid and clear cell carcinomas; and higher GALNT6 levels are significantly associated with poorer patient survivals...
June 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28364869/a-vaginal-estradiol-softgel-capsule-tx-004hr-has-negligible-to-very-low-systemic-absorption-of-estradiol-efficacy-and-pharmacokinetic-data-review
#17
REVIEW
James A Simon, David F Archer, Ginger D Constantine, James H Pickar, Julia M Amadio, Brian Bernick, Shelli Graham, Sebastian Mirkin
This paper reviews the efficacy, safety, and systemic absorption of estradiol with TX-004HR, an investigational, low-dose 17β-estradiol vaginal softgel capsule, designed to treat vulvar and vaginal atrophy (VVA) in postmenopausal women, with an improved user experience. In phase 2 (NCT02449902) and phase 3 REJOICE (NCT02253173) studies, TX-004HR significantly improved the proportions of vaginal superficial and parabasal cells and vaginal pH, and in the phase 3 study decreased the severity of dyspareunia, vaginal dryness, and vulvar and/or vaginal itching or irritation...
May 2017: Maturitas
https://www.readbyqxmd.com/read/28355090/consistency-of-effect-with-a-low-dose-estradiol-vaginal-capsule-tx-004hr-evaluating-improvement-in-vaginal-physiology-and-moderate-to-severe-dyspareunia-in-subgroups-of-postmenopausal-women
#18
Ginger D Constantine, Celine Bouchard, James H Pickar, David F Archer, Shelli Graham, Brian Bernick, Sebastian Mirkin
BACKGROUND: The 12-week, randomized, double-blind, placebo-controlled, multicenter, phase 3 REJOICE trial demonstrated that TX-004HR, an investigational, applicator-free, low-dose vaginal softgel capsule containing solubilized 17β-estradiol, effectively and rapidly treats symptoms of vulvar and vaginal atrophy (VVA) with negligible to very low systemic absorption. The aim of this analysis was to assess whether the efficacy of TX-004HR varies with age, body mass index (BMI), uterine status, pregnancy status, and vaginal delivery...
June 2017: Journal of Women's Health
https://www.readbyqxmd.com/read/28323042/comparison-of-intravaginal-6-5mg-0-50-prasterone-0-3mg-conjugated-estrogens-and-10%C3%AE-g-estradiol-on-symptoms-of-vulvovaginal-atrophy
#19
REVIEW
David F Archer, Fernand Labrie, Marlene Montesino, Céline Martel
The objective is to compare the effect of intravaginal dehydroepiandrosterone (DHEA, prasterone), conjugated equine estrogens (CEE) and estradiol (E2) on moderate to severe dyspareunia and/or vaginal dryness. In a review of available data, independent prospective, randomized, double-blind and placebo-controlled Phase III 12-week clinical trials involved daily administration of 6.5mg (0.50%) prasterone, daily (21days on/7days off) 0.3mg CEE, twice weekly 0.3mg CEE or 10μg E2 daily for 2 weeks followed by twice weekly for 10 weeks...
March 18, 2017: Journal of Steroid Biochemistry and Molecular Biology
https://www.readbyqxmd.com/read/28277131/macro-regional-variation-in-attitudes-toward-and-experiences-of-vulvar-and-vaginal-atrophy-among-italian-post-menopausal-women-a-post-hoc-analysis-of-revive-survey-data
#20
Rossella E Nappi, Martire Particco, Nicoletta Biglia, Angelo Cagnacci, Costantino Di Carlo, Stefano Luisi, Anna Maria Paoletti
Italian participants in the European REVIVE survey reported that vaginal and vulvar atrophy (VVA) impaired various aspects of their lives, notably the ability to enjoy sex. The aim of the present study was to explore regional differences in knowledge, experiences, and treatment of VVA in the Italian REVIVE sample (n = 1000), which was analyzed according to region of residence. While many respondents were unfamiliar with the VVA condition, most could relate their VVA symptoms to the menopause. The rate of diagnosis of VVA was twice as high in Central Italy as in the North-East...
February 21, 2017: Gynecological Endocrinology
keyword
keyword
5071
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"